扶正抑癌汤伍用化疗治疗大肠癌术后38例疗效观察

目的：探讨扶正抑癌汤在大肠癌术后巩固治疗中的临床价值。方法：对３８例大肠癌术后患者采用扶正抑癌汤加化疗治疗（治疗组），并与３１例单纯化疗（对照组）进行对照。结果：治疗组患者体力状况好于对照组（Ｐ＜００１），中位生存时间（３１４个月）长于对照组（１８０个月）；治疗组生存率高于对照组（Ｐ＜００５），毒副反应发生率低于对照组（Ｐ＜００５或Ｐ＜００１）；治疗组复发率（２１０５％）低于对照组（４８３４％，Ｐ＜００５）；治疗组治疗后免疫功能改善（Ｐ＜００５或Ｐ＜００１）。结论：扶正抑癌汤配合化疗在大肠癌术后巩固治疗中，其免疫调节、抑癌抗复发、延长生存周期等作用优于单纯化疗。

英文摘要:

Objective: To investigate the clinical value of Fuzheng Yiai Decoction (FZYAD) in postoperational large intestinal Cancer after treatment. Methods: Thirty eight cases treated by FZYAD combined with chemotherapy in the treated group were observed and compared with 30 patients in the control group treated with chemotherapy alone. Results: After treatment, patients′ physical strength of the treated group was better than that of the control group (P<0 01), meanwhile, the median survival time was longer (31.4 months vs 18 months, P<0 01), the survival rate higher (P<0 05), and the recurrence rate lower (21.05% vs 48.34%, P<0 05) in comparison of the treated group and the control group. Moreover, the cellular immune function of the treated group was improved after treatment. Conclusions: In treatment of postoperational large intestinal cancer, the effect of FZYAD combined chemotherapy is better than that of chemotherapy alone in immune function regulation, cancer inhibition, relapse prevention and survival time prolongation.

关闭